Side-by-side · Research reference

5-Amino-1MQvsChonluten

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-MechanisticHUMAN-REVIEWED8/38 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

01Mechanism of Action

Parameter

5-Amino-1MQ

Chonluten

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Bronchial epithelial cells and respiratory mucosa tissue complexes

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Chonluten

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

Once or twice daily

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

In vitro mechanistic

Duration

8–12 weeks per cycle

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

—

Typical protocol dose

—

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

Route

—

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

Clinical validation

—

None (PubMed indexed)

04Side Effects & Safety

Parameter

5-Amino-1MQ

Chonluten

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

Unknown — no pharmacokinetic studies available

Documented adverse events

—

No published safety data in PubMed-indexed literature

Theoretical risks

—

Peptide hypersensitivity, GI intolerance (uncharacterized)

Pregnancy / lactation

—

No data — avoid

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Chonluten

·Known hypersensitivity to peptide components

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

05Administration Protocol

Parameter

5-Amino-1MQ

Chonluten

1. Form

Oral capsule. No injection.

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

2. Administration

Take with water, fasted preferred.

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

3. Timing

Morning fasted.

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

4. Storage

Room temp ≤25 °C, dry place.

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

5. Caveat

Monitor B-vitamin status with chronic use.

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.